CORVax

BIOLOGICAL2 trials

Sponsors

Chase Heaton, MD, Providence Health & Services

Conditions

Metastatic Head and Neck Squamous Cell CarcinomaRecurrent Head and Neck Squamous Cell CarcinomaSARS-CoV-2Unresectable Head and Neck Squamous Cell Carcinoma

Phase 1

CORVax12: SARS-CoV-2 Spike (S) Protein Plasmid DNA Vaccine Trial for COVID-19 (SARS-CoV-2)

TerminatedNCT04627675

Providence Health & ServicesSARS-CoV-2

Start: 2020-12-30End: 2022-12-28Updated: 2024-10-26

Phase 2

Optimizing Antitumor Immunity Using Plasmid Electroporation, Pembrolizumab, and Epacadostat

TerminatedNCT03823131

Chase Heaton, MDMetastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Unresectable Head and Neck Squamous Cell Carcinoma

Start: 2019-05-02End: 2022-07-31Updated: 2023-05-09

Related Papers

Treatment of skin tumors with intratumoral interleukin 12 gene electrotransfer in the head and neck region: a first-in-human clinical trial protocol

Radiology and Oncology2022-05-1022 citations